WallStSmart
HYFT

ImmunoPrecise Antibodies Ltd.

NASDAQ: HYFT · HEALTHCARE · BIOTECHNOLOGY

$1.19
+0.00% today

Updated 2026-04-30

Market cap
$54.19M
P/E ratio
P/S ratio
1.93x
EPS (TTM)
$-0.10
Dividend yield
52W range
$0 – $3
Volume
0.3M

ImmunoPrecise Antibodies Ltd. (HYFT) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
+28.6%
Last 4 quarters
Revenue YoY growth
-35.9%
Most recent quarter
EPS YoY growth
+91.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-4.1%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.1%
2025-12-15
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-12$-0.06-63.3%$1.28$1.24-3.1%
2025-12-15$-0.07-366.7%$1.77$1.68-5.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-01-31$-0.04$-0.06-63.3%$4.09M-35.9%
2025-10-31$-0.02$-0.07-366.7%$4.17M+52.5%
2025-07-31$-0.04$-0.09-109.3%$3.17M+26.4%
2025-04-30$-0.07$-0.05+28.6%$6.79M+4.4%
2025-01-31$-0.08$-0.66-725.0%$6.38M+3.2%
2024-10-31$-0.07$-0.06+8.3%$2.73M-56.1%
2024-07-31$-0.11$2.51M-55.5%
2024-04-30$-0.49$6.50M+15.0%
2024-01-31$-0.08$6.18M
2023-10-31$-0.08$6.23M
2023-07-31$-0.11$5.63M
2023-04-30$-0.15$5.65M

Frequently asked questions

Has ImmunoPrecise Antibodies Ltd. beaten earnings estimates?
ImmunoPrecise Antibodies Ltd. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of +28.6% over the last 1 quarters.
How does HYFT stock react to earnings?
HYFT stock has moved an average of -4.1% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is ImmunoPrecise Antibodies Ltd.'s revenue growth rate?
ImmunoPrecise Antibodies Ltd. reported year-over-year revenue growth of -35.9% in its most recent quarter, with EPS growing +91.1% year-over-year.